Physician profile
Erin E Slater
NPI 1336108240
$1,396.78
in general payments reported to CMS, 2019-2025
11 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $357 · 2023: $85.36 · 2024: $510 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $433.56 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $362.80 | 2021-2023 | Airsupra |
| Glaxosmithkline, LLC. | $296.75 | 2022-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $62.39 | 2024-2025 | Eohilia |
| Genzyme Corporation | $56.31 | 2023 | |
| Amgen INC. | $48.48 | 2024-2025 | Uplizna |
| Optinose US, INC. | $38.80 | 2024 | |
| Alk-Abello, INC | $35.55 | 2025 | Pre-Pen, Alternaria Tenuis, Standardized Mite D. Farinae |
| Inspire Medical Systems, INC. | $26.80 | 2025 | Inspire |
| Precigen, INC. | $17.79 | 2025 | |
| Kaleo, INC. | $17.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.